Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.

被引：0

作者：

Janne, Pasi A.

Ramalingam, Suresh S.

Yang, James Chih-Hsin

Riely, Gregory J.

Bunn, Veronica

Jin, Shu

Zhou, Caicun

Camidge, D. Ross

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[2] Emory Univ, Atlanta, GA USA

[3] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, New York, NY USA

[5] Takeda Dev Ctr Americas Inc, Lexington, MA USA

[6] Shanghai Pulm Hosp, Shanghai, Peoples R China

[7] Univ Colorado, Canc Ctr, Aurora, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9099

引用

页数：1

共 38 条

[1] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
Ramalingam, Suresh S.
Zhou, Caicun
Kim, Tae Min
Kim, Sang-We
Yang, James Chih-Hsin
Riely, Gregory J.
Mekhail, Tarek
Nguyen, Danny
Campelo, Maria Rosario Garcia
Felip, Enriqueta
Vincent, Sylvie
Jin, Shu
Bunn, Veronica
Lin, Jianchang
Lin, Huamao Mark
Mehta, Minal
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
Gonzalvez, Francois
Vincent, Sylvie
Baker, Theresa E.
Gould, Alexandra E.
Li, Shuai
Wardwell, Scott D.
Nadworny, Sara
Ning, Yaoyu
Zhang, Sen
Huang, Wei-Sheng
Hu, Yongbo
Li, Feng
Greenfield, Matthew T.
Zech, Stephan G.
Das, Biplab
Narasimhan, Narayana, I
Clackson, Tim
Dalgarno, David
Shakespeare, William C.
Fitzgerald, Michael
Chouitar, Johara
Griffin, Robert J.
Liu, Shengwu
Wong, Kwok-Kin
Zhu, Xiaotian
Rivera, Victor M.
CANCER DISCOVERY, 2021, 11 (07) : 1672 - 1687
[3] Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
Ramalingam, S. S.
Zhou, C.
Kim, T. M.
Yang, J. C-H.
Riely, G. J.
Mekhail, T.
Nguyen, D.
Garcia Campelo, M. R.
Felip, E.
Misch, D.
Kaur, M.
Bunn, V.
Lin, M.
Zhang, P.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1004 - S1004
[4] Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study
Popat, Sanjay
Ramalingam, Suresh
Kim, Tae Min
Yang, James
Riely, Gregory
Mekhail, Tarek
Nguyen, Danny
Garcia Campelo, Maria Rosario
Felip, Enriqueta
Spira, Alexander
Piotrowska, Zofia
Bazhenova, Lyudmila
Vincent, Sylvie
Jin, Shu
Griffin, Celina
Diderichsen, Paul
Gupta, Neeraj
Bunn, Veronica
Lin, Jianchang
Lin, Huamao
Churchill, Eric
Mehta, Minal
Zhou, Caicun
Janne, Pasi
LUNG CANCER, 2022, 165 : S30 - S31
[5] Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
Nguyen, D.
Ramalingam, S. S.
Spira, A.
Riely, G. J.
Kim, T. M.
Yang, J. C-H.
Piotrowska, Z.
Campelo, M. R. Garcia
Felip, E.
Bazhenova, L.
Jin, S.
Griffin, C.
Diderichsen, P. M.
Gupta, N.
Bunn, V.
Lin, J.
Churchill, E. N.
Mehta, M.
Zhou, C.
Janne, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S968 - S969
[6] Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins) + NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study
Misch, D.
Ramalingam, S.
Zhou, C.
Kim, T. M.
Yang, J. C.
Riely, G.
Mekhail, T.
Nguyen, D.
Campelo, Garcia M. R.
Felip, E.
Bunn, V.
Lin, H.
Zhang, P.
Jaenne, P.
Kaur, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 96 - 97
[7] Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
Yang, J. C-H.
Ramalingam, S. S.
Kim, T. M.
Kim, S-W.
Riely, G. J.
Mekhail, T.
Nguyen, D.
Campelo, M. R. Garcia
Felip, E.
Bazhenova, L.
Jin, S.
Griffin, C.
Bunn, V.
Lin, J.
Churchill, E. N.
Mehta, M.
Janne, P. A.
Zhou, C.
ANNALS OF ONCOLOGY, 2021, 32 : S975 - S975
[8] Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer
Yang, James Chih-Hsin
Zhou, Caicun
Janne, Pasi A.
Ramalingam, Suresh S.
Kim, Tae Min
Riely, Gregory J.
Spira, Alexander, I
Piotrowska, Zofia
Mekhail, Tarek
Campelo, Maria Rosario Garcia
Felip, Enriqueta
Bazhenova, Lyudmila
Jin, Shu
Kaur, Manmit
Diderichsen, Paul M.
Gupta, Neeraj
Bunn, Veronica
Lin, Jianchang
Churchill, Eric
Mehta, Minal
Nguyen, Danny
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 95 - 106
[9] Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
Janne, P.
Ramalingam, S.
Kim, T.
Yang, J. C.
Riely, G.
Mekhail, T.
Nguyen, D.
Garcia Campelo, M. R.
Felip, E.
Jin, S.
Griffin, C.
Bunn, V.
Lin, J.
Mehta, M.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S960 - S960
[10] Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Riely, Gregory J.
Neal, Joel W.
Camidge, D. Ross
Spira, Alexander, I
Piotrowska, Zofia
Costa, Daniel B.
Tsao, Anne S.
Patel, Jyoti D.
Gadgeel, Shirish M.
Bazhenova, Lyudmila
Zhu, Viola W.
West, Howard L.
Mekhail, Tarek
Gentzler, Ryan D.
Nguyen, Danny
Vincent, Sylvie
Zhang, Steven
Lin, Jianchang
Bunn, Veronica
Jin, Shu
Li, Shuanglian
Janne, Pasi A.
CANCER DISCOVERY, 2021, 11 (07) : 1688 - 1699

← 1 2 3 4 →